SSG
AVDL

Summit Securities Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Summit Securities Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-685
Closed -$5.36K – 1087
2025
Q1 		$5.36K Buy
+685
New +$5.74K ﹤0.01% 601
2024
Q1 		– Sell
-2,422
Closed -$34K – 472
2023
Q4 		$34K Buy
+2,422
New +$28.5K ﹤0.01% 428
2015
Q3 		– Sell
-600
Closed -$13K – 367
2015
Q2 		$13K Buy
+600
New +$10.8K 0.01% 353

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Securities Group's AVDL Position: Q2 2025 in Review

Summit Securities Group sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 685 shares — an estimated $5.36K sold.

Summit Securities Group first reported a position in AVDL in Q2 2015 and held it in 3 quarters. The position peaked at $34K in Q4 2023. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Summit Securities Group reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 685 Avadel Pharmaceuticals shares in Q2 2025, an estimated $5.36K.
  • Summit Securities Group first reported a position in Avadel Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Summit Securities Group's Avadel Pharmaceuticals position peaked at $34K in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.